Aclaris Therapeutics, Inc. (ACRS) on Tuesday reported positive interim results from a Phase 1a single-ascending dose (SAD) and multiple-ascending dose (MAD) trial of ATI-052.
The company said ATI-052 was well tolerated and demonstrated a favorable safety profile across all SAD and MAD cohorts. The drug candidate showed a potential best-in-class pharmacokinetic profile, including an effective half-life of at least 26 days. Treatment-emergent adverse events were predominantly Grade 1, with no Grade 3 events related to the study drug and no serious adverse events reported.
Aclaris said it expects to initiate a Phase 1b proof-of-concept trial in atopic dermatitis imminently, followed by a Phase 1b proof-of-concept trial in asthma in the first quarter of 2026. Top-line data from both trials are expected in the second half of 2026.
The company is also planning a Phase 2b trial of ATI-052 in atopic dermatitis, which is expected to begin in the second half of 2026.
Aclaris shares were up more than 4% in pre-market trading after closing at $2.65, down 7.98% on Monday.
For comments and feedback contact: editorial@rttnews.com
Business News
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.